Adjuvant Subcutaneous Trastuzumab for HER2‐Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study
Oncologist - United States
doi 10.1634/theoncologist.2018-0065
Full Text
Open PDFAbstract
Available in full text
Date
July 17, 2018
Authors
Publisher
Alphamed Press